## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Rauch Lee M.				2. Issuer Name and Ticker or Trading Symbol Ensysce Biosciences, Inc. [ENSC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director				
(Last) (First) (Middle) C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022						-	Officer (g	ve title below)	Oth	er (specify belo	w)	
(Street) LA JOLLA, CA 92037				4. If Amendment, Date Original Filed(Month/Day/Year)						-	6. Individual or Joint/Group FilingCheck Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						es Acqui	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year		Execution Date, if Co (In (Month/Day/Year)				4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)  (A) or Amount (D)		of (D) (	Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
	Conversion Date Execution Date or Exercise (Month/Day/Year) any		3A. Deemed Execution Date, if	4. Transaction Code		5. Numb	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(	Ownershi Form of Derivativ Security: Direct (D or Indirects)	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercisal		piration te	Title	Amour or Numbe of Shares		(Instr. 4)	(Instr. 4)	
Stock Option	\$ 0.425	06/23/2022		A		15,000		(1)	06	/23/2032	Comn	115 00	<u>(1)</u>	35,000	D	

#### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Rauch Lee M. C/O ENSYSCE BIOSCIENCES, INC. 7946 IVANHOE AVENUE, SUITE 201 LA JOLLA, CA 92037	X						

#### **Signatures**

/s/ Lee Rauch	06/27/2022
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value \$0.0001 (1) per share, with a per share exercise price of \$0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.